http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2022-03-31 11:12:282022-03-31 11:12:28Mission Therapeutics authorised to initiate first clinical trial for lead DUB program, MTX652, in kidney disease
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2022-03-22 10:18:312022-03-22 10:18:31Mission Therapeutics to participate in BIO-Europe Spring 2022
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2022-03-15 15:47:032022-03-15 15:47:03Mission Therapeutics to present at the 2nd Annual Target Protein Degradation Europe Summit
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2022-03-07 11:56:502022-03-07 12:03:47Mission Therapeutics to participate in the 2022 Babraham Research Campus Signalling Event
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00Kelly Southernhttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngKelly Southern2022-02-21 09:00:512022-02-21 09:00:51Mission Therapeutics to participate in the BMO Biopharma Spotlight Series 2022
